The Kinetix Group, in partnership with Consulting at McCann Health, has authored a research report that has been accepted to be exhibited as a poster presentation at ISPOR 2019 in New Orleans on May 20, 2019.
| NEW YORK, March 26, 2019 /PRNewswire/ -- The Kinetix Group, in partnership with Consulting at McCann Health, has authored a research report that has been accepted to be exhibited as a poster presentation at ISPOR 2019 in New Orleans on May 20, 2019. The report is titled, “Which Outcome & Quality Measures Do Leading KOLs Who Treat Nonalcoholic Steatohepatitis (NASH) Recommend flor Value-Based Contracting Across Multiple Stakeholders?”, and analyzes primary and secondary research, including insights gathered from 12 US key opinion leaders (KOLs).
Currently, there are no FDA-approved NASH drug treatments; 4 drugs in phase III trials are among approximately 55 in research and development. Experts state that the global market for NASH could exceed $35 billion. Given the shift to value-based medicine and the significant cost implications of NASH, the study explored which outcomes and quality measures KOLs would recommend for value-based contracting. The KOLs involved in this study have been integral advisors on a real-world evidence initiative launched in 2018 by The Kinetix Group, in partnership with NASH Network (NASHNET). The collaboration is focused on improving NASH care delivery through a pilot with leading academic medical centers using Echosens’ FibroScan® system device as part of a standard workup to appropriately identify patients with progressive nonalcoholic fatty liver disease (NAFLD). FibroScan® is a non-invasive technology that quickly provides a quantitative assessment of liver stiffness and fat at the point of care. The Kinetix Group and NASHNET are committed to pioneering and defining the best practice model for NASH care delivery. This study demonstrates the need for an appropriate NASH care model that is standardized and evidence-based in the evolution towards value-based care. The poster presentation will be exhibited May 18-22, 2019, at the Ernest N. Morial Convention Center in New Orleans. Author discussion will be held from 6:00 pm – 7:00 pm on May 20, 2019. Click here to register and learn more. For more information, please contact Kristen Shea at kristenshea@thekinetixgroup.com NASH Network (NASHNet): Nonalcoholic Steatohepatitis (NASH) is a challenging high-volume chronic condition that lacks a standardized care delivery model. Our multidisciplinary teams of experts are here to change that. NASHNET is a global Centers of Excellence Network represented by leading healthcare systems committed to NASH care delivery innovation. Our charter members are collaborating to solve for key challenges across the NASH spectrum, including care coordination, population health, real-world evidence, and clinical trials. To learn more, go to www.nashnetwork.org. The Kinetix Group (TKG) empowers life science companies to effectively engage with health system and payer customers by developing strategies and real-world solutions aimed at impacting the right patient, at the right time, with the right care. TKG also works directly with health systems and payers to build and implement value-based delivery models for identified patient populations. To learn more, go to www.thekinetixgroup.com. Echosens is an innovative, high-technology company offering a full range of non-invasive products and services supporting physicians in their assessment and management of patients with chronic liver diseases at the point of care. To learn more, go to https://www.echosens.us.
SOURCE The Kinetix Group |
View original content to download multimedia:
